AtCor launches improved blood pressure test

AtCor Medical Holdings (ASX:ACG) has launched an improved version of its SphygmoCor central aortic blood pressure and arterial stiffness monitoring system.

The Sydney-headquartered company has debuted SphygmoCor XCEL at the 22nd European Society of Hypertension Congress in London this week.

The new iteration of the system automates and improves the process of data capturing. It can also allow simultaneous brachial and central aortic blood pressure measurement.

The system is non-invasive, and allows carotid femoral pulse wave velocity measurement using inflatable cuffs while the patient is fully-clothed.

SphygmoCor XCEL is now being sold in Australia, Europe and some Asian markets, and is expected to launch in the US later this year.

“The SphygmoCor XCEL system... can measure brachial and central aortic blood pressure in 60 seconds,” AtCor CEO Duncan Ross said. “We believe this product has great commercial potential and removes an important barrier to faster adoption in the clinical market.”

According to AtCor, over 2,700 SphygmoCor systems are currently in use worldwide.

AtCor Medical was founded in 1994 by Professor Michael O'Rourke, Ross Harricks and Keith Stewart. The company went public with a $15 million IPO at $0.50 per share in 2005, and was added to the ASX list in November that year.

AtCor Medical (ASX:ACG) shares were trading unchanged at $0.079 by around 2:30pm on Wednesday.